Autonomix Reports Positive FDA Feedback Supporting 510(k) Pathway to U.S. Clearance

FDA pre-submission feedback supports pursuing a Class II clearance pathway for the company's standalone sensing platform through substantial equivalence to a previously cleared device. The company estimates potential initial U.S. clearance in approximately 15 months, reducing regulatory-pathway uncertainty but leaving approval and commercialization risk outstanding.